The earnings miss may pressure PVLA shares near-term, but the strong cash runway and upcoming NDA submission provide a catalyst. Watch for pre-NDA meeting outcomes and pipeline milestones in 2H 2026.
Price Chart
Executive Summary
Palvella Therapeutics reported Q1 2026 EPS of -$1.20, missing consensus of -$0.93 by 29%, as R&D and G&A expenses rose sharply. Despite the miss, the company highlighted strong cash of $261.9M and reiterated NDA submission for QTORIN rapamycin in microcystic LMs in 2H 2026, with potential approval and launch in 1H 2027.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$1.20 missed consensus of -$0.93 (29% miss)
- Net loss of $15.8M vs $8.2M in Q1 2025, driven by higher R&D and G&A costs
- Cash, cash equivalents and short-term investments of $261.9M as of March 31, 2026
- NDA submission for QTORIN rapamycin in microcystic LMs on track for 2H 2026
- Phase 3 SELVA study met all primary and secondary endpoints; pre-NDA meeting granted
Financial Impact
EPS miss of $0.27 per share
Risk Factors
- EPS miss may lead to negative sentiment and near-term selling
- Clinical and regulatory risks ahead of NDA submission and approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210605 |
| Document: pvla-20260507.htm | 0001193125-26-210605 |
| Document: pvla-ex99_2.htm | 0001193125-26-210605 |
| Document: 0001193125-26-210605-index-headers.html | 0001193125-26-210605 |
| Document: 0001193125-26-210605-index.html | 0001193125-26-210605 |
| Document: 0001193125-26-210605.txt | 0001193125-26-210605 |
| 8-K Data (Synthetic) | 0001193125-26-210605 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 144 | $155.47 $132.47 | ▼ −14.79% | ▼ −13.61% | $132.47 (−14.79%) |
Aug 9, 2026 7w ago | Institutional Cluster | $152.22 $157.00 | ▲ +3.14% | ▲ +4.05% | $132.47 (−12.97%) |
Aug 4, 2026 8w ago | 8-K | $151.99 $150.55 | ▼ −0.95% | ▲ +0.29% | $132.47 (−12.84%) |
Jul 30, 2026 9w ago | Press Release | $150.19 $150.33 | ▲ +0.09% | ▼ −3.87% | $132.47 (−11.80%) |
Jul 28, 2026 9w ago | Press Release | $142.84 $148.24 | ▲ +3.78% | ▲ +0.40% | $132.47 (−7.26%) |
Jun 30, 2026 13w ago | 8-K | $152.82 $141.77 | ▼ −7.23% | ▼ −6.20% | $132.47 (−13.32%) |
Jun 22, 2026 14w ago | Press Release | $118.84 $157.24 | ▲ +32.31% | ▲ +32.46% | $132.47 (+11.47%) |
Jun 16, 2026 15w ago | 8-K | $110.12 $149.68 | ▲ +35.92% | ▲ +35.72% | $132.47 (+20.30%) |
Jun 11, 2026 16w ago | Institutional Cluster | $106.38 $151.04 | ▲ +41.98% | ▲ +40.09% | $132.47 (+24.53%) |
May 15, 2026 20w ago | 8-K | $114.24 $116.51 | ▲ +1.99% | ▼ −0.13% | $132.47 (+15.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access